Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 244, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2022.114864
Keywords
2-Arylamino-[1; 2; 4]triazolo[1; 5-a]pyrimidine; Anticancer agents; Tubulin inhibitors
Categories
Funding
- Natural Science Foun-dation of Guangdong Province, China
- Science and Technology Program of Guangzhou City, China
- [2018B030311067]
- [201707010198]
Ask authors/readers for more resources
A series of new compounds were designed and synthesized as potential tubulin polymerization inhibitors, among which one compound showed excellent antiproliferative activity and selectivity against cancer cells, as well as significant tubulin polymerization inhibitory activity.
Following our previously reported compound 3, we designed and synthesized a series of new 2-(substituted amino)-[1,2,4]triazolo[1,5-a]pyrimidines as potential tubulin polymerization inhibitors. Among them, analogue 4k, having a 3-hydroxy-4-methoxyphenylamino group, was observed to display excellent antiproliferative ac-tivity toward HeLa, HCT116, A549, and T47D with the IC50 values of 0.31, 1.28, 3.99 and 10.32 mu M, respec-tively, which were approximately 32, 48, 4, and 5-fold improvement compared with 3. Importantly, 4k possessed significant selectivity in inhibiting cancer cell lines over the normal HEK293 cells. Moreover, futher mechanism analysis demonstrated that 4k caused G2/M arrest, induced cells apoptosis in HeLa cells, and manifested sig-nificant tubulin polymerization inhibitory activity with the IC50 value of 4.9 mu M, which is comparable to CA-4 (IC50 = 4.2 mu M). The observations performed in this study reveal that 2-arylamino- [1,2,4]triazolo[1,5-a]py-rimidines represent a novel class of tubulin polymerization inhibitors with potent antiproliferative efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available